Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis is a research paper published in Journal for ImmunoTherapy of Cancer (2021). On theSindex it has a DataRank of 0.637. It has been cited 69 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.637
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NHLBI
Grant: K08HL131987
NIH/NCI
Grant: K08CA197966
Lung Cancer Research Foundation
Grant: LC180245
National Cancer Institute
Grant: P30CA016056
National Center for Advancing Translational Sciences of the NIH
Grant: UL1TR001412
NCATS NIH HHS
Grant: KL2 TR001413
NHLBI NIH HHS
Grant: K23 HL153582
National Institutes of Health
Grant: 5K08CA197966-06
Adoptive Cell Therapy with Rejuvenated Antigen-Specific T Cells
National Institutes of Health
Grant: 5K08HL131987-02
Galectin-3-Mediated Post-Ischemic Myocardial Dysfunction and its Inhibition by a Novel Peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline
National Institutes of Health
Grant: 5P30CA016056-40
Roswell Park Cancer Institute Cancer Center Support Grant
National Institutes of Health
Grant: 3UL1TR001412-08S3
Buffalo Clinical and Translational Research Center
Department of Defense
University of Buffalo
Melanoma Research Alliance
Roswell Park Alliance Foundation, Roswell Park Cancer Institute
FWCI
3.41
Citation Percentile
1.0%
Influential Citations
4
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals